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Mammalian RF-amide peptides, which all share a conserved carboxyl-terminal Arg–Phe–
NH2 sequence, constitute a family of five groups of neuropeptides that are encoded by
five different genes. They act through five G-protein-coupled receptors and each group of
peptide binds to and activates mostly one receptor: RF-amide related peptide group binds
to NPFFR1, neuropeptide FF group to NPFFR2, pyroglutamylated RF-amide peptide group
to QRFPR, prolactin-releasing peptide group to prolactin-releasing peptide receptor, and
kisspeptin group to Kiss1R. These peptides and their receptors have been involved in the
modulation of several functions including reproduction, feeding, and cardiovascular regu-
lation. Data from the literature now provide emerging evidence that all RF-amide peptides
and their receptors are also involved in the modulation of nociception. This review will
present the current knowledge on the involvement in rodents of the different mammalian
RF-amide peptides and their receptors in the modulation of nociception in basal and chronic
pain conditions as well as their modulatory effects on the analgesic effects of opiates.
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INTRODUCTION
A tetrapeptide Phe–Met–Arg–Phe–NH2 (FMRF-NH2) has been
isolated in 1977 by Price and Greenberg and was described as hav-
ing cardioexcitatory properties in the neverid clam Macrocallista
nimbosa (1). Thereafter, using specific antibodies for the COOH-
terminus of this peptide, FMRF-NH2 immunoreactive peptides
were identified in several species including mouse (2, 3) and the
first two mammalian FMRF-NH2-like peptides, neuropeptides FF
and AF, were further isolated from bovine brain (4). They represent
the first members of the family of mammalian RF-amide pep-
tides, which all share a conserved carboxy-terminal Arg–Phe–NH2
sequence. Additional members of this family and their receptors
were identified and cloned in the late 90s and early 2000s (5). At
present, five groups of mammalian RF-amide peptides have been
described including neuropeptide FF (NPFF), RF-amide related
peptide (RFRP), pyroglutamylated RF-amide peptide (QRFP),
prolactin-releasing peptide (PrRP), and kisspeptin groups. The
sequences of human and rodents RF-amide peptides, their dif-
ferent names as well as the name of their receptors are listed in
Table 1.
Several RF-amide peptide receptors have been discovered:
NPFFR1 (alias GPR147), NPFFR2 (alias GPR74), QRFPR (alias
GPR103), prolactin-releasing peptide receptor (PrRPR) (alias
GPR10), and Kiss1R (alias GPR54). They all belong to the G-
protein-coupled receptor family, and share approximately 50%
homology. Each receptor binds mostly one group of RF-amide
Abbreviations: ASIC, acid-sensing ion channels; CNS, central nervous system;
DOR, δ-opioid receptor; DRG, dorsal root ganglia; i.c.v., intracerebroventricular;
i.th., intrathecal; KOR, κ-opioid receptor; MOR, µ-opioid receptor; NPAF, neu-
ropeptide AF; NPFF, neuropeptide FF; PrRP, prolactin-releasing peptide; QRFP,
pyroglutamylated RF-amide peptide; RFRP, RF-amide related peptide.
peptide: NPFFR1 binds RFRP peptides, NPFFR2–NPFF group,
QRFPR–QRFP group, PrRPR–PrRP group, and Kiss1R–kisspeptin
group. However, in vitro it has been shown that NPFFR1/2 display
a good affinity for all mammalian RF-amide peptides, whereas,
QRFPR, PrRPR, and Kiss1R show a high level of discrimination
for their endogenous peptides (6).
In this review, we will focus on the involvement of the five mam-
malian RF-amide peptide groups and their respective receptors in
the modulation of nociception in rodents.
NPFF, RFRP, AND NPFF RECEPTORS 1/2
Neuropeptide FF group of peptides includes NPFF and neuropep-
tide AF (NPAF), while RFRP group comprises RFRP-1 and -3 (also
called NPSF and NPVF). NPFF and NPAF are derived from the
same precursor, whereas RFRP-1 and RFRP-3 are generated from
another precursor (7–10). These different peptides can all activate
NPFFR1 and NPFFR2, but RFRP group displays better activity
for NPFFR1, and NPFF group preferentially activates NPFFR2
(5). NPFFR1 and NPFFR2 are both coupled to Gi (9, 11–13).
They display around 50% amino acid identity, and are encoded
by two different genes concomitantly identified in 2000 by dif-
ferent research teams (9, 11, 12). NPFFR1 and NPFFR2 are also
called OT7T022/GPR147 and HLWAR77/GPR74, respectively (see
Table 1). They are expressed in all vertebrate species examined and
are highly conserved, underlining their important role (14).
NPFF, NPAF, AND NPFFR2
Localization in the pain pathways
NPFF and NPAF. Neuropeptide FF and NPAF were first iso-
lated from bovine medulla oblongata and described as having
anti-opioid activity on morphine-induced analgesia in the rat
(4, 15). The distribution of NPFF/NPAF peptides and mRNA
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Table 1 | Summary of nomenclature and sequences for mammalian RF-amide peptides and their receptors.
Group Peptide Species Uniprot accession
number
Sequence Receptor name
NPFF NPFF Human O15130 SQAFLFQPQRF-NH2 NPFFR2
Rat Q9WVA9 NPAFLFQPQRF-NH2 GPR74
Mouse Q9WVA8 SPAFLFQPQRF-NH2 HLWAR77
NPAF (NPSF for the last
eight residues)
Human O15130 AGEGLNSQFWSLAAPQRF-NH2
Rat Q9WVA9 EFWSLAAPQRF-NH2
Mouse Q9WVA8 QFWSLAAPQRF-NH2
RFRP RFRP-1 (NPSF, GnIH) Human Q9HCQ7 MPHSFANLPLRF-NH2 NPFFR1
Rat Q9ESQ9 VPHSAANLPLRF-NH2 GPR147
Mouse Q9ESQ8 OT7T022
RFRP-3 (NPVF) Human Q9HCQ7 VPNLPQRF-NH2
Rat Q9ESQ9 ANMEAGTMSHFPSLPQRF-NH2
Mouse Q9ESQ8 VNMEAGTRSHFPSLPQRF-NH2
QRFP QRFP43 (43RFa, P518) Human P83859 <EDEGSEATGFLPAAGEKTSGPLGNLAEELNGYSRKKG
GFSFRF-NH2
QRFPR
GPR103
Rat P83860 <EDSGSEATGFLPTDSEKASGPLGTLAEELSSYSRRKGG
FSFRF-NH2
AQ27
SP9155
Mouse Q8CE23 <EDGSSEAAGFLPADSEKASGPLGTLAEELSSYSRRKGG
FSFRF-NH2
QRFP26 (26RFa) Human P83859 TSGPLGNLAEELNGYSRKKGGFSFRF-NH2
Rat P83860 ASGPLGTLAEELSSYSRRKGGFSFRF-NH2
Mouse Q8CE23
PrRP PrRP31 Human P81277 SRTHRHSMEIRTPDINPAWYASRGIRPVGRF-NH2 PrRPR
Rat P81278 SRAHQHSMETRTPDINPAWYTGRGIRPVGRF-NH2 GPR10
Mouse B7U2G4 hGR3
PrRP20 Human P81277 TPDINPAWYASRGIRPVGRF-NH2 UHR-1
Rat P81278 TPDINPAWYTGRGIRPVGRF-NH2
Mouse B7U2G4
Kisspeptin Kisspeptin-54 (metastin) Human Q15726 GTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAVLVQR
EKDLPNYNWNSFGLRF-NH2
Kiss1R
GPR54
Kisspeptin-52 Rat Q7TSB7 TSPCPPVENPTGHQRPPCATRSRLIPAPRGSVLVQREKDMSA
YNWNSFGLRY-NH2
OT7T175
AXOR12
Mouse Q6Y4S4 SSPCPPVEGPAGRQRPLCASRSRLIPAPRGAVLVQREKDLS
TYNWNSFGLRY-NH2
Kisspeptin-10 Human Q15726 YNWNSFGLRF-NH2
Rat Q7TSB7 YNWNSFGLRY-NH2
Mouse Q6Y4S4
Sequences in bold correspond to the conserved carboxyl-terminal sequence between human, rat and mouse peptides.
has been extensively reviewed by Yang and collaborators (14).
In this review, the authors pointed out that one must remain
vigilant regarding the NPFF distribution by immunohistochem-
istry or radioimmunoassay, because the antibodies first used were
against the COOH-terminus of NPFF, which is shared by other
RF-amide peptides, thus results may be non-specific to NPFF. Nev-
ertheless, NPFF presence in rodents has largely been reported in
discrete central nervous system (CNS) areas by radioimmunoas-
say, immunohistochemistry, or in situ hybridization studies. The
highest levels recorded were in the dorsal horn of the spinal cord
and in the posterior lobe of the pituitary gland [see Ref. (14, 16)].
Fibers containing NPFF in the spinal cord seems to have intrinsic
spinal origin (17). Most studies have reported the absence of NPFF
mRNA or immunoreactivity in dorsal roots ganglia (DRG) except
Allard et al. (18) who showed the presence of NPFF immunore-
activity in DRG, but at low level and only after blocking axonal
transport [see Ref. (16)].
Neuropeptide AF (also called NPSF in rodents; see Table 1) has
been detected in mouse and rat spinal cord as well as in human
cerebrospinal fluid [see Ref. (14, 19–21)].
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NPFFR2. The detailed distribution in rodents of both protein and
mRNA for NPFFR2 is reviewed in Ref. (14–16, 22, 23). NPFFR2
mRNA has been detected by in situ hybridization and qRT-PCR
in several brain regions of rodents including thalamic nuclei,
hypothalamus, and superficial layers of spinal cord (10–12, 24).
Using immunohistochemistry and western blot, the presence of
NPFFR2 has also been detected in ventral tegmental area, hip-
pocampus, hypothalamus olfactory tubercle, and spinal cord (25).
NPFFR2 distribution in rodents has been widely described by
using binding experiments (11, 26–32). The highest NPFFR2 bind-
ing sites are found in the olfactory bulb (of mice but not rat), in
several thalamic nuclei, and in superficial layers of the spinal cord.
However, it must be noted that, in these studies, the radiolabeled
ligands used for the detection of NPFFR2 are not highly selective
for this receptor and could therefore limit the relevance of the
conclusions.
Like for NPFF, results concerning the presence of NPFFR2 and
its mRNA in DRG or in primary afferent terminals in the spinal
cord are controversial, with some studies supporting their pres-
ence and other their absence in this region [see Ref. (14–16)].
NPFFR2 mRNA has been detected in rat dorsal root ganglia and
trigeminal ganglia (11). Different studies have shown a decrease
of NPFFR2 binding in rats after dorsal rhizotomy, neonatal cap-
saicin treatment, sciatic nerve section, or spinal cord ligation (29,
33) while Lombard and collaborators did not see any decrease of
binding sites after neonatal capsaicin treatment or dorsal rhizo-
tomy suggesting that, in the rat spinal cord, NPFF receptors are
mostly post-synaptically expressed (34).
Overall, the plurality of techniques leading to the same distrib-
ution pattern supports the presence of NPFFR2 in different brain
structures and spinal cord and is consistent with its potential role
in the modulation of nociception and sensory input.
Modulation of nociception
Effects of NPFF/NPAF on basal nociception and opiate analge-
sia. The modulation of nociception by NPFF/NPAF has been
largely studied and reviewed in Ref. (5, 14–16, 22, 23, 35). Table 2
summarizes the effect of the different RF-amide peptides on noci-
ception. NPFF has been described as having two different effects
on pain perception depending on the site of administration. When
administrated by intrathecal (i.th.) injection, NPFF showed anti-
nociceptive effect, which may be considered opioid-like effect
as it provoked analgesia and potentiated opioid effects. When
administrated at the supra spinal level via intracerebroventricular
(i.c.v.) injection, NPFF had a pro-nociceptive effect characterized
by a reversal of morphine analgesia, indicating that it displays
anti-opioid properties [for details, see Ref. (15)]. Furthermore,
inhibition of morphine analgesia induced by i.c.v. injection of
NPFF in mice was blocked when NPFF was co-administered with
RF9 (either i.c.v. or subcutaneously), a selective antagonist of
NPFFR1/2 (6, 36–38). RF9, also potentiated opiate analgesic effects
and blocked opioid-induced hyperalgesia and analgesic tolerance
both in mice and rats (38, 39). Altogether, these results support
that NPFF action on nociception and opiate analgesia is medi-
ated by NPFF receptors and that this peptide and its receptor are
part of an anti-opioid system that is involved in the homeostatic
control of opiates action. Hypothesis explaining NPFF anti-opioid
properties are further described below. We can notice that in most
reports, NPFF alone had no effect on basal nociceptive threshold
but efficiently reversed morphine analgesia, suggesting that NPFF
anti-opioid properties depend on opioid receptors stimulation and
points to their interconnected mechanisms of action. However,
it is noteworthy that in few studies, NPFF administered alone
by i.c.v. lowered the nociceptive threshold measured by the tail
flick test in rat, which is consistent with anti-opioid properties
of this peptide (4, 40). Interestingly, in PrRPR lacking mice, NPFF
administration did not reverse morphine analgesia any more, indi-
cating that at least some NPFF actions require a functional PrRPR
[see below; (41)]. Finally, NPFF-related peptides delayed the rate
of acid-sensing ion channels (ASIC) desensitization causing an
enhancement of acid gated currents (42), which are known to have
pain modulatory properties (43). In addition, it has been demon-
strated that expression of ASIC3 increased under inflammatory
conditions (44). Therefore, NPFF may also modulate pain through
ASICs. However, these results were obtained with high concen-
trations of RF-NH2 peptides, thus questioning the physiological
relevance of these observations.
Neuropeptide AF has been shown to display NPFF-like bioac-
tivity. NPAF injection, in the lateral ventricle of mice, increased or
decreased morphine-induced analgesia in the tail flick test depend-
ing on NPAF and morphine amounts used (50) while another
study showed that i.c.v. administration of NPAF in mice potently
reversed morphine-induced analgesia in the tail flick test (19).
I.th. administration of a low dose of NPAF in the rat potentiated
morphine anti-nociception in tail flick and paw-pressure tests and
efficiently reversed morphine analgesic tolerance (49). Altogether,
these results demonstrate NPAF implication in opioid-modulating
system. Like NPFF, NPAF can increase the amplitude of the sus-
tained current of ASIC (57) indicating its eventual role in neuron
excitability and then in nociception. However, in ASIC3 knockout
mice, nociceptive behavior induced by NPAF subcutaneous injec-
tion is similar than in wild type animals, suggesting that ASIC3 is
not involved in this effect (58).
Anti-opioid properties. Tolerance is defined by the loss of effi-
cacy of a given compound after prolonged treatment, which leads
to the necessity to increase the dose to reach the same effect.
Two different hypotheses have been proposed to explain toler-
ance to morphine. One is based on different molecular mech-
anisms including functional selective desensitization of receptor
signaling, receptor endocytosis, and degradation (59–63). The
second one proposes the existence of a homeostatic equilibrium
between the anti-nociceptive opioid system and pro-nociceptive
anti-opioid systems (64, 65). In this model, activation of the
opioid system by an exogenous opiate produces analgesia, but
also stimulates the release of endogenous anti-opioid molecules,
which produces a pro-nociceptive effect. This pro-nociceptive
effect ramps up during chronic administration of the opiate
and thus opposes to its analgesic effect. It is then necessary to
increase opiate doses to overcome the activation of anti-opioid
systems and produce an analgesic effect, thus explaining the tol-
erance described following chronic opioid treatment. Moreover,
upon cessation of the opiate treatment, the opioid system is no
longer activated while the anti-opioid system remains activated by
www.frontiersin.org October 2014 | Volume 5 | Article 158 | 3
Ayachi and Simonin RF-amide peptides in pain modulation
Table 2 | Summary of the effects of mammalian RF-amide peptides on the modulation of nociception.
Group Peptide Injection Basal nociception Inflammatory pain Neuropathic pain
NPFF NPFF (or
analog)
i.th. Analgesia and potentiation of
opioid effects [see Ref. (15)]
Attenuates allodynia and thermal
hyperalgesia (45, 46)
Attenuates allodynia (45–47)
i.c.v. No effect or decreases basal
nociceptive threshold and
reverses morphine analgesia
[see Ref. (15)]
Attenuates tactile allodynia (46, 47)
Intraperitoneal Attenuates flinching behavior in
formalin test (48)
Decreases mechanical
hypersensitivity (48)
NPAF i.th. Potentiates morphine analgesia
and reverses morphine analgesic
tolerance (49)
i.c.v. Increases/decreases morphine
analgesia (19, 50)
RFRP RFRP-1 (NPSF,
GnIH)
i.th. Thermal anti-nociception and tactile
anti-allodynia (51)
i.c.v. Decreases morphine
analgesia (10)
Decreases morphine
analgesia (10)
RFRP-3 (NPVF) i.c.v. Decreases thermal nociceptive
threshold (6); potentiates/
decreases/no effect on morphine
analgesia (6, 37, 50)
QRFP QRFP26
(26RFa)
i.th. No effect on mechanical or
thermal nociception (52, 53)
Decreases mechanical allodynia;
inhibits agitation behavior in
formalin test (52, 54)
Antiallodynic effect (53)
i.c.v. No effect on thermal nociception
(54); decreases thermal
nociceptive threshold (6)
Inhibits agitation behavior in
formalin test (52, 54)
PrRP PrRP20 i.th. No effect (55)
Intracerebral Analgesia [nucleus tractus
solitary; (55)]
Attenuates tactile allodynia
(periaqueductal gray, nucleus
tractus solitarius) or no effect
[caudal ventrolateral medulla; (55)]
i.c.v. Hyperalgesia (6, 41, 55)
Kisspeptin kisspeptin-54 Intraplantar Nocifensive response; decreases
thermal pain threshold (56)
kisspeptin-10 i.c.v. Hyperalgesia and anti-morphine
activity (6)
endogenous anti-opioid molecules, which explains the decrease in
the basal nociceptive threshold or hyperalgesia observed following
disruption of chronic morphine treatment. This phenomenon is
called opioid-induced hyperalgesia.
Neuropeptide FF has been shown to participate in the adap-
tive processes that counteract the opioid effects or change in
the nociceptive threshold leading to opioid-induced hyperalgesia
and tolerance. Indeed, increase in NPFF-like immunoreactivity
has been observed in the brain and spinal cord during chronic
or acute morphine treatment (66–68), supporting the key role
of NPFF in these processes [see Ref. (35, 64)]. It has also been
shown that reducing NPFF expression by central administration
of antibodies or antisense oligonucleotides attenuated the toler-
ance to morphine analgesia (69, 70). Moreover, when NPFFR1/2
were pharmacologically blocked in rats or mice with RF9, there
was a potentiation of opiate analgesic effects, a prevention of
the development of opiate tolerance and an abolition of hyper-
algesia induced by acute or chronic administration of different
opiates including, fentanyl, heroin, and morphine (38, 39). Fur-
thermore, triple knockout mice for µ-, δ-, κ-opioids receptors
(corresponding to MOR, DOR, and KOR, respectively) are hyper-
algesic, which supports the idea that MOR/DOR/KOR deletion
certainly affects the balance between opioid and anti-opioid sys-
tems, and then, may lead to an increase in NPFF system efficacy.
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Accordingly, MOR/DOR/KOR triple knockout mice showed an
increase in NPFFR2 binding sites in several brain region and spinal
cord (71). Finally, it has been shown that chronic i.c.v. infusion of
NPFF downregulated MOR binding sites in the rat brain (72),
whereas injection of antiserum against NPFF (anti-NPFF IgG)
upregulated MOR binding sites (73). This suggests that density of
MOR is regulated by NPFF, raising another possible way to induce
anti-opioid effects.
Regarding morphine withdrawal and rewarding effects, NPFF
also shows anti-opioid properties. NPFF i.c.v. injection produced
an abstinence syndrome in morphine-dependent rats (66), and
IgG i.c.v. injection from an antiserum against NPFF attenuated
naloxone-induced withdrawal syndrome (70, 74), suggesting that
NPFF modulates the different effects of opioids. I.c.v. injection
of NPFF analog (dNPA) in mice counteracted the c-Fos expres-
sion induced by morphine in the shell of nucleus accumbens (75)
known to be required for the acquisition of morphine-conditioned
place preference (76). NPFFR1/R2 blockade with RF9 increased
morphine-induced conditioned place preference and decreased
naltrexone-precipitated withdrawal syndrome (38). Accordingly,
injection of the NPFF analog (1DMe)-NPYF inhibited the reward-
ing effect of morphine (77), and acute administration of NPFF
inhibited morphine-induced hyperlocomotion (78).
Overall, these results suggest that NPFF/NPFFRs system
opposes to opioid effects, highlighting its role as an anti-opioid
system.
Cellular effect. Hypothesis to explain the activation of
NPFF/NPFFRs anti-opioid system, by the stimulation of the opi-
oid system, may be that the neuronal circuitry implicated in both
systems is interconnected, or it may exist a crosstalk between recep-
tors in the same neurons involving a correlation/crosscheck in
the cellular effects (79). In agreement with this second hypoth-
esis, it has been shown that in rat spinal ganglion neurons the
NPFF analog (1DMe)-NPYF reversed the inhibition by DAMGO
of depolarization-evoked rise in intracellular Ca2+ (80), suggest-
ing that NPFF could block the inhibition of morphine analgesia
by reversing the effect of mu agonists on Ca2+channels. Another
possibility to explain anti-opioid activity of NPFFR2 receptors is
based on physical interaction between NPFFR2 and MOR. In fact,
it has been shown that NPFF agonist promoted a heteromeric
association between NPFFFR2 and MOR that changed the lateral
diffusion of MOR, which seems to move MOR away from its sig-
naling partners, thus reducing response to opioids (81). Moreover,
NPFF have been shown to modify the G-protein environment of
MOR, which may also participate in the mechanism by which this
peptide reduces the inhibitory activity of opioids (82). More gen-
erally, stimulation of NPFF receptor seems to provoke changes in
MOR-associated signaling that could occur by receptor heteromer-
ization and/or alteration in signaling transduction pathways [see
Ref. (35)].
Concerning the pro-opioid properties, Mollereau et al. have
shown that, similarly to opioid agonists, NPFF increased voltage-
dependent potassium outward currents in F-11 DRG cell line
(hybridoma derived from rat DRG and mouse neuroblastoma),
which may explain the similar anti-nociceptive actions of NPFF
and opioid agonists at the spinal level (83). Regarding the opioid
potentiating effect of intrathecally injected NPFF, it has been pro-
posed that activation of NPFF receptors could result in a functional
blockade of δ opioid autoreceptors in the spinal cord, which are
involved in an inhibitory feedback on Met-enkephalin release (84).
However, the molecular mechanisms involved in this effect are still
unclear and this hypothesis is not supported by studies in Chinese
hamster ovary cell line showing that NPFF analog (1DMe)-NPYF
had no intrinsic activity but enhanced DOR-mediated inhibition
of forskolin-stimulated cAMP accumulation and phosphorylation
of ERK2 (85).
Involvement of NPFF system in persistent pain. Neuropeptide
FF and NPFFR2 seem to be implicated in inflammatory pain.
Indeed, several studies, using different models of inflammatory
pain,have shown that inflammation-induced modulation of NPFF
or NPFFR2 at the mRNA and protein levels [see Table 3 in Ref.
(14)]. For instance, persistent pain induced by carrageenan inflam-
mation upregulated NPFF and NPFFR2 gene expressions in the rat
spinal cord, suggesting an involvement of spinal NPFF system in
inflammatory pain (8, 24, 86). In the rat, it has also been shown
that during acute colonic inflammation there is an up-regulation
of supraspinal NPFFR2 (86). Moreover, in the spinal cord of rats
with tibio-tarsal joint inflammation (induced by Mycobacterium
butyricum in Freund’s adjuvant injected into the tibio-tarsal joint),
there is an increase of [125I]-1DMe-NPYF binding (87) while car-
rageenan induced an increase of NPFF immunoreactive cell bodies
in spinal cord (88) and an increase of NPFFR2 immunoreactivity
in primary afferent terminals (24). Otherwise, it has been shown
that NPFF administration (i.th. or i.c.v.) attenuated allodynia
induced by injection of Freund’s Complete Adjuvant in the rat paw
(46) while (1DMe)-NPYF i.th. administration decreased mechan-
ical allodynia and thermal hyperalgesia induced by carrageenan
inflammation (45). More recently, another study showed that
an intraperitoneal injection of the NPFFR2 agonist AC-263093
attenuated flinching behavior in formalin test, and thermal hyper-
algesia induced by carrageenan injection in hotplate test (48).
Very recently, an in vitro study using LPS-stimulated macrophages
has shown that NPFF suppressed the production of nitric oxide,
an important signal transmitter during inflammatory processes,
suggesting a possible anti-inflammatory action of this peptide
(89). This effect was blocked by a pretreatment with RF9, indi-
cating that it is mediated by NPFF receptors. Finally, in mice with
chronic inflammatory pain induced by complete Freund’s adju-
vant, the decrease of morphine rewarding properties were associ-
ated with an increase of NPFFR2 agonist [125I]-EYWSLAAPQRF-
NH2 binding in several brain regions involved in morphine reward
including the shell of the nucleus accumbens, the major islands of
Calleja and the ventral endopiriform nucleus. Altogether, these
data indicate that NPFF and NPFFR2 are probably upregulated
in different models of inflammatory pain in rodents and that
NPFF displays antiallodynic and anti-hyperalgesic effects in these
models.
In rats with neuropathic pain, NPFF mRNA was not upreg-
ulated neither in the spinal cord nor in the brainstem, while
NPFFR2 mRNA was slightly upregulated only in the brainstem
(8, 86). NPFF administrations either i.c.v., i.th. or directly into
the periaqueductal gray attenuated tactile allodynia induced by
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chronic neuropathy in rats (46, 47). Moreover, i.th. adminis-
tration of the NPFF analog (1DMe)-NPYF decreased cold and
mechanical allodynia observed in rats with spinal nerve ligation
(45) and intraperitoneal injection of NPFFR2 agonist AC-263093
attenuated mechanical hypersensitivity in the same model of neu-
ropathy (48). In summary, although NPFF and NPFFR2 mRNA
do not seem to be strongly regulated in neuropathic pain mod-
els, NPFF and NPFF-related compounds display antiallodynic
properties in neuropathic animals.
In a model of cancerous pain induced by melanoma cells
injected in the hind paw of the mouse, the binding of NPFFR2 ago-
nist [125I]-EYWSLAAPQRF-NH2 increased in several brain areas
involved in the rewarding properties of opiates, similarly to what
was observed in a model of chronic inflammation (see above).
This increase of binding was associated with a decrease of mor-
phine’s motivational properties tested with the place preference
paradigm. These data suggest that NPFF contributes to the sup-
pression of morphine rewarding effects in this model of cancerous
pain (90).
Overall, NPFF and NPFF-related compounds have been shown
to display antiallodynic/hyperalgesic properties in different mod-
els of chronic pain, which contrast with the pro-nociceptive anti-
opioid properties of NPFF that have been observed in animals that
were chronically treated with opiates.
RFRP-1, RFRP-3, AND NPFFR1
The gene encoding RFRP-1 and RFRP-3 have been identified and
cloned in the beginning of 2000s by two research teams through
databases searches (9, 10). These two different peptides, also
known as NPSF and NPVF, derived from the same precursor pro-
tein and constitute the RFRP group [(9, 10); see Table 1]. RFRP-1
seems to be the mammalian homolog of LPLRF-amide, a peptide
isolated in 1983 in avian brain (3) and of gonadotropin-inhibitory
hormone (GnIH) characterized from quail brain (91). RFRP-1
and RFRP-3 activate preferentially NPFFR1, which triggers the
Gi/o signal transduction pathway (9, 11).
Localization in the pain pathways
RFRP-1 and RFRP-3. Neurons containing RFRP-1 and RFRP-3
proteins and RFRP mRNA have been found by using immuno-
histochemical analyses and in situ hybridization in rat and mouse
CNS (9, 10, 92–96). Their highest level has been found in the hypo-
thalamus (periventricular and ventromedial nucleus), and fibers
containing RFRP-1 and RFRP-3 are widely distributed in the brain
(94). These results were confirmed very recently by the analysis of
transgenic rats expressing an enhanced green fluorescent protein
tagged to the RFRP promoter (97). Neurons containing RFRP
immunoreactivity and mRNA are distinct from those contain-
ing NPFF (94). In mice, RFRP-immunoreactive fibers were found
in the superficial layer of spinal trigeminal nucleus and dorsal
horn of the spinal cord (93), while in rats, low levels of RFRP-1
immunoreactivity and no mRNA were detected in these regions
(51, 94). From these observations, Pertovaara et al. (51) suggested
that RFRP neurons localized in rat hypothalamus may contribute
to well-known descending pain modulatory pathways (98), which
project to nucleus of the solitary tract and spinal cord.
NPFFR1. NPFFR1 transcript was identified both in RT-qPCR
and in situ hybridization experiments in several structures of the
rat CNS. Highest signals were detected in the lateral septum and
in various hypothalamic and thalamic nuclei (9–11). Accordingly,
a high level of NPFFR1 binding sites was found in these regions
both in the rat and mouse (30–32). NPFFR1 mRNA and binding
sites were weakly or not detectable in the superficial layers of the
spinal cord, depending on the strains of rodents used (10, 11, 31).
Overall, there is a good correlation between the distribution of
NPFFR1 receptor and its endogenous ligands RFRP-1/-3.
Modulation of nociception
Modulatory effects of both RFRP-1 and RFRP-3 on nociception
have been reported (see Table 2). I.c.v. injection of RFRP-1, when
given alone, had no effect on hot plate latencies in the rat but
when co-administrated with morphine, it decreased or blocked
morphine analgesia in hot plate and formalin tests (10). These
data suggest that, like NPFF, RFRP-1 action depends on opioid
receptors activation, supporting its role in an anti-opioid system
related to the opioid system. In neuropathic rats, RFRP-1 produced
pain suppressive effects depending on the modality of the noxious
test and the localization of the injection (51). Indeed, i.th. injection
of RFRP-1 induced thermal anti-nociception (tail flick test) and
tactile anti-allodynia (Von Frey filament), while injection in the
solitary tract nucleus produced only mechanical anti-hyperalgesia
(paw-pressure test). Furthermore, tactile anti-allodynia produced
by RFRP-1 was attenuated by naloxone, indicating that opioid
receptors are involved in the spinal action of RFRP-1.
In mice, i.c.v. injection of VPNLPQRF-NH2 (human RFRP-
3) in the lateral ventricle has been reported to either potentiate
morphine analgesia at high doses [10–32 nmol; (50)] or decrease
morphine analgesia at similar doses [20 nmol; (37)]. Conversely,
i.c.v. injection in mice of RFRP-3 from mouse origin (10 nmol) had
no effect on morphine analgesia but significantly decreased ther-
mal nociceptive threshold when injected alone and this effect was
reversed by RF9 (6). In SH-SY5Y cells transfected with NPFFR1
and endogenously expressing mu and delta opioid receptors,
RFRP-3 acted like opioids by inhibiting adenylyl cyclase activity
and voltage-gated Ca2+ currents, whereas preincubation of those
cells with RFRP-3 induced an anti-opioid activity characterized
by a decrease of response to opioids on calcium signaling (99).
Finally, NPFFR1 was shown to be downregulated in several brain
regions of triple MOR/DOR/KOR knockout mice, suggesting an
interaction between opioid and RFRP/NPFFR1 systems (71).
Altogether, these results indicate that RFRP-1/3 play a role in the
modulation of nociception and opioid effects,presumably via their
receptor NPFFR1. However, if we consider that no NPFFR1 has
been found in the spinal cord of rodents and that RFRP-1/-3 pep-
tides can bind to NPFFR2 subtype, this receptor may be involved
in the spinal nociceptive modulating effect of these peptides (6).
Moreover, RFRPs as well as NPFF and NPAF have also been shown
to bind and activate some Mrgs (mas-related genes), which are
G-protein-coupled receptor expressed in DRG by a specific sub-
set of sensory neurons (100, 101), suggesting that these receptors
could also represent relevant targets for nociceptive effects of these
peptides.
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QRFP AND QRFP RECEPTOR
Pyroglutamylated RF-amide peptide and its receptor QRFPR are
the most recently discovered mammalian RF-amide peptide and
receptor, respectively (102–104). QRFPR is also known as GPR103,
AQ27, SP9155, and QRFP as P518, 26RFa/43RFa (see Table 1).
43RFa is a NH2-terminally elongated form of 26RFa. Both peptides
arise from the same precursor and were isolated from human
hypothalamus and spinal cord, while only 43RFa was isolated from
rat brain (102, 105). The primary sequences of human and rodent
26RFa display more than 80% identity (102). The nomenclature
QRFP26 and QRFP43 will be used throughout the text for 26
and 43RFa, respectively. QRFPR have been shown to activate the
Gq/Gi signal transduction pathways in heterologous cells (103,
104), while QRFP26 has been shown to stimulate cAMP produc-
tion by rat pituitary cells (102). In rodents, two receptor subtypes
have been identified QRFPR1 and QRFPR2 (105, 106). Human
QRFPR shares 83/84 and 79/82% amino acid identity with mouse
and rat QRFPR1 and QRFPR2, respectively, while mouse QRFPR1
and R2 share with each other 75% amino acid identity (105).
QRFP26 and 43 have also been shown to display high affinity for
and agonist activity at both NPFF receptor subtypes (6, 107).
LOCALIZATION IN THE PAIN PATHWAYS
Pyroglutamylated RF-amide peptide mRNA distribution has been
studied in detail in mouse and rat CNS by in situ hybridiza-
tion (102, 103, 105, 106). QRFP transcript was detected almost
exclusively in the hypothalamus including ventromedial hypothal-
amic nucleus, the lateral hypothalamic area, the arcuate nucleus,
the retrochiasmatic area, and periventricular nucleus [see Ref.
(108)]. In mouse, low levels of QRFP transcript were identified by
RT-qPCR in spinal cord (105). In naive rat, QRFP-like immunore-
activity was observed in the L5 DRG (52, 53) where it was mainly
located in small to medium sized neurons suggesting a relationship
with C-fibers and therefore nociceptive transmission (53). Similar
observations were made after a partial spinal nerve ligation (53).
Conversely to QRFP transcript, QRFPR1 and R2 mRNAs are
widely distributed in the CNS of rodents including spinal cord
[see Ref. (108)]. High expression levels were observed in several
different hypothalamic and thalamic nuclei as well as brainstem
nuclei including dorsal raphe nucleus and the locus coeruleus that
are critical regions involved in pain control. In mice, the mRNA
distribution of QRFPR1 and R2 displayed no overlap with each
other (105). However, the transcript for both receptor subtypes
has been detected in the spinal cord (105, 109). Like QRFPR tran-
scripts, QRFP binding sites are widely distributed in the brain
and the spinal cord with a high density in the superficial lay-
ers of the dorsal horn [see Ref. (108)]. QRFP binding sites have
been described in nuclei involved in processing of pain, such as
the parafascicular thalamic nucleus, the locus coeruleus, the dor-
sal raphe nucleus, the parabrachial nucleus. However, in the rat,
QRFPR mRNA-containing cells are particularly expressed in the
midbrain, the pons, and the medulla oblongata, while QRFP bind-
ing sites are widely distributed throughout the brain and the spinal
cord. These differences may be explained by the fact that QRFP
also bind to NPFFR2 (110). QRFPR-like immunoreactivity was
observed in the superficial lamina of the spinal dorsal horn but not
in DRG (52). Taken together, these data suggest the involvement
of QRFP-QRFPR system in the nociceptive transmission and/or
integration.
MODULATION OF NOCICEPTION
As summarized in Table 2, in naïve rats, i.th. injection of QRFP26
had no effect neither on mechanical nor on thermal nociception
[tested with the hotplate test and Von Frey filaments, respectively;
(52, 53)], and i.c.v. injections had no effect on thermal nociception
(54). However, a recent study showed that i.c.v. administration
of QRFP26 in mice provoked a decrease of thermal nociceptive
threshold (6). This discrepancy could be explained by several dif-
ferences between these studies including the species (rat versus
mouse) and nociceptive test used (hot plate versus tail immer-
sion) as well as amount of QRFP injected (three or four times
higher in the rat study than in the mouse study).
The effect of QRFP26 has also been examined in different
models of persistent pain in rats including inflammatory pain (car-
rageenan and formalin tests) and neuropathic pain (partial sciatic
nerve ligation). Concerning inflammatory pain, it has been shown
that i.th. injection of QRFP26 attenuated the level of mechani-
cal allodynia induced by paw carrageenan injection, while i.th. or
i.c.v. injections of this peptide inhibited the phase 1 and phase
2 of the agitation behavior induced by paw formalin injection
(52, 54). Similarly, i.th. and i.c.v. injections of QRFP produced an
antiallodynic effect in a model of partial sciatic nerve ligation (53).
These data together with the observations made on naïve ani-
mals in the same studies suggest that QRFP modulates nociceptive
transmission only during inflammation or neuropathy and has
no effect on physiological nociceptive transmission. In addition,
Yamamoto et al. pointed out that i.th. but not i.c.v. injection
of QRFP suppressed the expression of Fos-like immunoreactiv-
ity induced by paw formalin injection in the superficial layers of
the spinal dorsal horn, suggesting thus, an implication of QRFP
in spinal sensitization induced by paw formalin, carrageenan
injection, or partial spinal nerve ligation (52).
Recently, a novel QRFP peptide named TC26RFa has been iden-
tified from Chinese tree shrews (111). I.p. injection of TC26RFa in
mice induced analgesia in thermal nociceptive tests (tail flick and
hot plate tests), in a model of visceral pain, and in the formalin test,
and stimulated secretion of anti-inflammatory factors from RAW
264.7 cells (111). In the future, it will be important to determine
whether these effects occur through the direct activation of mouse
QRFPR and which receptor subtype is involved in these effects.
PrRP AND PrRP RECEPTOR
Prolactin-releasing peptide, named as such for its prolactin-
releasing activity, has been first isolated by Hinuma and collabora-
tors as stimulator of arachidonic acid release from cells expressing
an orphan G-protein-coupled receptor cloned from human pitu-
itary and called hGR3 (112). This receptor is nearly identical to a
previously cloned orphan receptor called GPR10 (113) and its rat
ortholog was cloned from hypothalamus and called UHR-1 (114).
Its official name is presently prolactin-releasing peptide recep-
tor (PrRPR). Both short (PrRP20) and NH2-terminally elongated
(PrRP31) forms of PrRP originate from the same precursor pro-
tein of 98 amino acids [see Table 1 and Ref. (115)]. Several results
suggest that PrRPR is coupled to either Gq or Gi/o. Indeed, in
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CHO cells expressing PrRPR, PrRP induced intracellular Ca2+
influx and a decrease of forskolin-stimulated intracellular cAMP
production (112). It has also been shown that PrRP, in rat pituitary
tumor cells, stimulated the activation of ERK that was blocked by
inactivating Gi/o by pertussis toxin (116) while in HEK293 cells,
PrRPR stimulation induced intracellular Ca2+ influx but had no
effect on cAMP production (117). Interestingly, Lin et al. have
shown that PrRPR can associate with PSD-95/Disks-large/ZO-1
(PDZ) domain proteins (118). PDZ domain proteins are involved
in mechanisms of scaffolding and targeting of proteins to specific
subcellular domains [see Ref. (119)]. It has also been shown that
PDZ domain proteins can interact with AMPA receptors, suggest-
ing that PrRPR may modulate neurotransmission at glutamatergic
synapses (118). Both PrRP20 and 31 bind with very high affinity to
PrRPR, but they have also been described to display high affinity
for and agonist activity at both NPFFR1 and NPFFR2 (6, 107, 120).
LOCALIZATION IN THE PAIN PATHWAYS
Prolactin-releasing peptide and PrRPR are widely distributed in
the nervous system. Their detailed distribution in rodent CNS has
been recently reviewed [see Ref. (23, 115, 121)]. In the rat (and
human) PrRP mRNA is expressed in several regions that have
been involved in the processing of nociceptive inputs including the
medulla oblongata and the nucleus of solitary tract as well as dor-
somedial hypothalamic nucleus. PrRP-immunoreactive fibers are
present in many brain regions including several areas important
for pain control including ventrolateral medulla, basolateral amyg-
daloid nucleus, and bed nucleus of the stria terminalis. No PrRP
has been detected in the spinal cord using immunohistochemistry
or in situ hybridization (55).
Prolactin-releasing peptide receptor mRNA is broadly
expressed in the brain and the highest expression is in the ante-
rior lobe of the pituitary (122). PrRPR mRNA has also been
shown to be highly expressed in lateral and medial parabrachial
nuclei, which are key region involved in the central processing of
nociceptive inputs from spinal lamina I–II and spinal trigeminal
cells (123). Autoradiographic binding experiments with [125I]-
PrRP31 only identified a strong signal in the reticular nucleus
of the thalamus as well as light binding in the periventricular
nucleus (124).
Overall, there is a good correlation between the localization of
PrRP fibers and its receptor. However, there are some discrepan-
cies that suggest that PrRPR might not be the only receptor for
PrRP. As in vitro binding experiments have shown that PrRP also
display high affinity for NPFFR1 and NPFFR2 (6, 107, 120), it
is tempting to speculate that these receptors could also represent
endogenous targets of PrRP in some brain areas. In agreement with
this hypothesis, we have shown that in rats the increase in blood
pressure and heart rate induced by i.c.v. administration of PrRP
is blocked by the NPFFR1/R2 selective antagonist RF9, while they
are still present in Otsuka Long-Evans Tokushima Fatty (OLETF)
rat strain, in which the GRP10 receptor gene was mutated (125).
MODULATION OF NOCICEPTION
Prolactin-releasing peptide modulates nociception in various ways
(see Table 2). Indeed, when administered in rats by i.th. injec-
tion, PrRP20 produced no significant anti-nociception, while
intracerebral injection of PrRP20 in the nucleus tractus solitar-
ius provoked a strong analgesia in tail flick and paw-pressure
tests (55). Conversely, PrRP induced significant hyperalgesia in
tail immersion test when administered i.c.v. in mice (6, 41) and
provoked a weak hyperalgesia in paw-pressure test when injected
in the rat caudal ventrolateral medulla (55), a structure known to
be involved in descending control of pain (126–128). These data
indicate that PrRP modulates nociception in rats and mice under
basal condition and nociceptive or anti-nociceptive actions of this
peptide depend on the site of injection.
It has also been shown that PrRP plays a role in the modula-
tion of nociception under neuropathic conditions. Indeed, in rats
with spinal nerve ligation, PrRP attenuated tactile allodynia when
it was injected in the periaqueductal gray or in the nucleus trac-
tus solitarius, but had no effect when administered in the caudal
ventrolateral medulla (55).
Based on the hypothesis that PrRPR participates to an anti-
opioid system, Laurent et al. studied the consequence of PrRPR
deletion on opiate response (41). They showed that, compared to
wild type, PrRPR-knockout mice have higher nociceptive thresh-
olds and stronger stress-induced analgesia, and these differences
are suppressed by naloxone. Moreover, the hyperalgesic effect
of i.c.v. administration of PrRP as well as its capacity to block
morphine analgesia was absent in PrRPR-knockout mice. These
animals also displayed a potentiation of morphine induced anal-
gesia, a reduction of morphine tolerance, an enhancement of
acquisition of morphine-induced conditioned place preference
and a decrease of the severity of naloxone precipitated morphine
withdrawal syndrome. These results suggest that PrRP–PrRPR sys-
tem participate in an anti-opioid system (41). More recently, we
have shown that the hyperalgesic and anti-morphine effects of
PrRP in wild type mice were blocked by the selective NPFFR1/R2
antagonist RF9, indicating that NPFF receptors are also critically
involved in these effects. Altogether, these data show that PrRPR
and NPFF receptors are both mandatory for the action of PrRP
on nociception. Similarly, these receptors seem both essential for
the action of NPFF since its anti-morphine effect was absent in
PrRPR-knockout animals (41) and was blocked in wild-type mice
by RF9 (6).
Overall, these data indicate the existence of a functional interac-
tion between NPFFR1/2 and PrRPR that is critical for the effect of
NPFF and PrRP on nociception. Whether this interaction occurs
through direct heterodimerization of these receptors or whether
it is due to expression of both receptors in different cells from the
same circuit remains to be investigated.
KISSPEPTIN AND Kiss1 RECEPTOR
Kisspeptin is a 54-amino acid peptide first discovered as a metas-
tasis suppressor, hence was also named metastin (129). In the
human, Kiss1 gene codes for a 145-amino acid precursor protein,
which is cleaved to the 54-amino acid protein (kisspeptin-54) or
into shorter products (kisspeptin-10, -13, -14) that all share the
same COOH-terminal Arg–Phe–NH2 sequence (130). In rodents,
the largest proteolytic product of the kisspeptin precursor is
composed of 52 amino acids (kisspeptin-52), and the RF-amide
sequence is substituted by an Arg–Tyr–NH2 motif (see Table 1).
Kisspeptin activates Kiss1R (also named GPR54, AXOR12, or
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OT7T175). This receptor has first been cloned from the rat brain
(131) and was deorphanized in 2001 by three independent research
groups (130, 132, 133). GPR54 is known to act via Gq/G11 signal
transduction pathways [see Ref. (134)]. Kisspeptin has also been
described as capable to activate different set of interconnected
signals in a cell type-dependent manner [see Ref. (135–138)]. It
has also been shown that kisspeptin-10, -13, and -54 display high
affinity binding and activate both NPFF receptor subtypes (6, 139,
140). Although Kisspeptin was originally identified as a metastasis
suppressor, this peptide and its receptor Kiss1R are now largely
recognized to have a central effect on neuroendocrine regulation
of reproduction. This aspect has recently been reviewed in details
by Pinilla and collaborators (141).
LOCALIZATION IN THE PAIN PATHWAYS
In the mouse and rat brain, kisspeptin transcript and protein have
been detected in several hypothalamic nuclei that are involved in
the control of gonadotropin secretion [see Ref. (142)]. Outside
of hypothalamus, kisseptin-immunoreactive fibers were identi-
fied in relatively few regions of mouse brain, some of which
being critically involved in the control of nociception including
the paraventricular thalamic nucleus, periaqueductal gray, and
locus coeruleus (143). In this study, the antisera specificity was
controlled with brains of Kiss1 knockout mice thus insuring that
the immunoreactivity observed is due to kisspeptin and not other
RF-amide peptides. In the rat, kisspeptin mRNA and immunore-
activity have been found in the dorsal horn of the spinal cord and
in L4/L5 DRG (144, 145). In DRG, kisspeptin is expressed in large-
sized neurons and also in unmyelinated small- and medium-sized
neurons, which are considered like nociceptors (145).
Kiss1 receptor mRNA has been detected in several regions of
rodents’ brain [see Ref. (142)]. In the mouse, by using X gal histo-
chemistry in a transgenic Kiss1RLacZ knock-in mouse, Herbison
et al. identified Kiss1R positive cells mainly in hypothalamus and
hippocampus, and in several discrete brain regions such as peri-
aqueductal gray and cuneate nucleus of brainstem, which are
involved in pain control (146). Kiss1 immunostaining have been
found in rat DRG neurons and in lamina I and II of the dorsal horn
of the spinal cord. In DRG, Kiss1R distribution is similar to that
of kisspeptin (145). Kiss1R has also been found, by immunohisto-
chemical analysis, in peripheral nerve endings of PGP9.5-positive
sensory fibers in the mouse skin (56).
All these data suggest that kisspeptin/Kiss1R system may play a
role in the modulation of nociception.
MODULATION OF NOCICEPTION
There are few reports that describe the effect of kisspeptin on
nociception in rodents (see Table 2). In naïve mice, intraplantar
injection of kisspeptin induced a small nocifensive response and
a decrease of thermal pain threshold in the hot plate test (56)
while i.c.v. administration of kisspeptin-10 induced hyperalgesia
and anti-morphine activity (6). However, these latter effects were
blocked by the NPFF1R/2R antagonist RF9 indicating that these
receptors are important for the effects of kisspeptin-10 on noci-
ception. If we consider that kisspeptins display high affinity for
Kiss1R and NPFFR1/R2, the receptor(s) that constitutes the direct
target of kisspeptins in these effects still remains to clarify.
In addition to its involvement in basal nociception, i.th. and
intraplantar injections of kisspeptin have been shown to provoke
hyperalgesia in the first and second phases of the formalin test
and to enhance TRPV1 phosphorylation at Ser800 at the site of
injection and ERK1/2 phosphorylation in the dorsal horn (56).
Moreover, in formalin test, the blockade of the endogenous action
of kisspeptin using an antagonist of Kiss1R, p234 (intraplantar
and i.th.), caused analgesia. From these results, Spampinato et al.
proposed that kisspeptin, by activating Kiss1R, may lead to periph-
eral nociceptive sensitization through the modulation of TRPV1
phosphorylation as well as to central sensitization via the acti-
vation of the ERK/MAPK pathway in the dorsal horn of the
spinal cord (56). Finally, in a model of chronic inflammatory
pain (complete Freund adjuvant), kisspeptin and Kiss1R tran-
scripts and proteins were upregulated in DRG and dorsal horn
neurons (145).
Altogether, these data attest that kisspeptin regulates pain
and/or nociceptive sensitization in mice, and may be predomi-
nantly implicated during inflammatory pain.
CONCLUSION
Mammalian RF-amide peptides and their receptors have been
implicated in the modulation of several functions including feed-
ing, reproduction, and cardiovascular regulation. Data from the
literature, including tissue distribution and in vivo activity of RF-
amide peptides, now provide emerging evidence that, not only
NPFF/NPFFR2 system but all RF-amide peptides and their recep-
tors are involved in the modulation of nociception, either in
basal or chronic pain conditions. Moreover, several of these pep-
tides and their receptors seem to participate to an anti-opioid
pro-nociceptive system that controls anti-nociceptive and possi-
bly other functions of opiates. Future studies, by using genetic
and selective pharmacological tools, will be necessary to clearly
delineate the role of each of these systems in the modulation of
nociceptive inputs. Ultimately, these studies should lead to the
identification of novel targets for pain treatment and for improv-
ing the efficacy of opiates and limit the development of tolerance
following chronic treatment.
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